Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 8/20 | 0.35 |
| ▸ | CDK2 | P24941 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | ATF1 | P18846 | 1/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522284 | 1.00 | LRRK2 (0.37) | LRRK2CYP1A2CDK1CDK2KDR | |
| SCHEMBL27228246 | 0.84 | LRRK2 (0.38) | LRRK2CYP1A2CDK1CDK2AURKA | |
| SCHEMBL30860873 | 0.84 | LRRK2 (0.38) | LRRK2CYP1A2CDK1CDK2AURKA | |
| SCHEMBL1774548 | 0.82 | CDK1 (0.47) | LRRK2CYP1A2CDK1CDK2KDR | |
| SCHEMBL14140885 | 0.82 | CDK1 (0.47) | LRRK2CYP1A2CDK1CDK2KDR | |
| SCHEMBL1774455 | 0.81 | KDR (0.51) | CDK1CDK2KDR | |
| SCHEMBL1774456 | 0.81 | KDR (0.51) | CDK1CDK2KDR | |
| SCHEMBL31081933 | 0.79 | TRPM8 (0.37) | LRRK2CYP1A2CDK1CDK2AURKA | |
| SCHEMBL26664440 | 0.79 | TRPM8 (0.37) | LRRK2CYP1A2CDK1CDK2AURKA | |
| SCHEMBL29107804 | 0.77 | LRRK2 (0.35) | LRRK2CYP1A2AURKANFKB1ATF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342185-B1 | SULFON SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2350026-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2342185-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010046035-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046034-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | CDK6, CDK4, CDK9 | LRRK2 2685/4885CYP1A2 640/4885CDK1 6/4885 |
| US-20110251222-A1 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE | CDK6, CDK4, CDK2 | LRRK2 2322/4885CYP1A2 760/4885CDK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.